Animal Drug Compounding Market Report 2026

Animal Drug Compounding Market Overview

• Animal Drug Compounding market size has reached to $1.79 billion in 2025 • Expected to grow to $2.58 billion in 2030 at a compound annual growth rate (CAGR) of 7.8% • Growth Driver: Pets' Expenditure Fueling Growth In The Animal Drug Compounding Market • Market Trend: Innovations In Feline-Friendly Formulations For Veterinary Medications • North America was the largest region in 2025.

What Is Covered Under Animal Drug Compounding Market?

Animal drug compounding is defined as the process of mixing and altering the ingredients of multiple medicines to create a customized medicine to treat the specific needs of a single animal or multiple animals. It is used for providing medical treatment for animals and is a process that plays an important role in veterinary medicine. The main animal drug compounding products are anti-infective agents, anti-inflammatory agents, hormones and substitutes, CNS agents, and other products. Anti-infective agents can be defined as medicines that are used to prevent various infections, such as antibiotics, antivirals, antifungals, and others. Anti-infective agents are used in animal drugs to kill infectious germs and stop the spread of infection in animals. The animal drug compounding is used for several types of animals, such as companion animals and livestock animals and administered through various routes, including oral, injectable, topical, and others. It is used in veterinary hospitals, veterinary clinics, and veterinary diagnostic centers.

What Is The Animal Drug Compounding Market Growth Forecast?

The animal drug compounding market size is expected to see strong growth in the next few years. It will grow to $2.58 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to advancements in drug compounding technologies, increasing adoption of AI for personalized medicine, growth in livestock treatment applications, rising awareness of customized veterinary therapies, expansion of veterinary diagnostic integration. Major trends in the forecast period include growing demand for personalized veterinary medications, expansion of injectable and oral compounded drugs, increasing focus on companion animal health, integration of veterinary diagnostics with drug compounding, adoption of customized hormonal and anti-inflammatory therapies.

Global Animal Drug Compounding Market Segmentation

1) By Animal Type: Companion Animals, Livestock Animals 2) By Product: Anti-Infective Agents, Anti-inflammatory Agents, Hormones And Substitutes, CNS Agents, Other Products 3) By Route Of Administration: Oral, Injectable, Topical, Other Routes Of Administrations 4) By Application: Veterinary Hospitals, Veterinary Clinics, Veterinary Diagnostic Centers Subsegments: 1) By Companion Animals: Dogs, Cats, Horses 2) By Livestock Animals: Cattle, Swine, Poultry, Sheep, Goats

What Is The Driver Of The Animal Drug Compounding Market?

Rising pet expenditure is expected to propel the growth of the animal drug compounding market going forward. Pet expenditure refers to the total amount of money spent on various expenses related to owning and caring for a pet. Pet expenditure contributes to the demand for tailored medications that cater to the unique needs of individual animals, thereby encouraging compounding pharmacies to continue providing these specialized services in veterinary care. For instance, in October 2023, the North American Pet Health Insurance Association (NAPHIA), a US-based trade organization published that in 2022, pet owners in the United States spent $136.8 billion on their dogs, cats, birds, and other companion animals, and this amount is projected to rise to $143.6 billion in 2023. Therefore, rising pet expenditure drives the animal drug compounding industry.

Key Players In The Global Animal Drug Compounding Market

Major companies operating in the animal drug compounding market are Akina Animal Health, Letco Medical LLC, The Pet Apothecary LLC, Vetsource Inc., BCP Veterinary Pharmacy, VetRxDirect LLC, Vetcentric Pty. Ltd., Pet Health Pharmacy, PetRx2Go, PetMed Express Inc., Diamondback Drugs, Brava Veterinary Pharmacy, Veterinary Pharmacies of America, MEDS Canadian Compounding Pharmacy, Chiron Compounding Pharmacy, Dougherty's Pharmacy, Pace Pharmacy, Aurora Compounding, ESSENTIAL PHARMACY COMPOUNDING VET, SCIRx Pharmacy, Summit Veterinary Pharmacy Ltd, ScriptWorks, Veterinary Specialty Pharmacy, Veterinary Pharmaceutical Solutions, Wedgewood Pharmacy LLC, Hoye’s Pharmacy, Triangle Compounding Pharmacy Inc., Vertisis Custom Pharmacy LLC

Global Animal Drug Compounding Market Trends and Insights

Major companies in the animal drug compounding market are developing innovative products, including feline-friendly formulations, to enhance the safety and effectiveness of medications tailored specifically for cats. Feline-friendly formulations refer to products specifically designed to be safe, effective, and appealing for cats. For instance, in September 2024, Wedgewood, a US-based veterinary pharmaceutical company launched compounded molnupiravir. Compounded molnupiravir is an antiviral drug specifically for treating Feline Infectious Peritonitis (FIP) in cats. It offers feline-friendly formulations of molnupiravir, available in various dosages designed to treat different forms of FIP, including effusive, non-effusive, neurological, and ocular types. This involves producing different dosages and flavors, including flavored oral oil suspensions and capsules, to meet the specific requirements of individual feline patients.

What Are Latest Mergers And Acquisitions In The Animal Drug Compounding Market?

In May 2024, MixLab, a US-based pharmaceutical laboratory, acquired Nexgen Animal Health for an undisclosed amount. With this acquisition, MixLab's aims to broaden veterinary compounding services to cover large animals while improving the pharmacy experience through advanced technology and increased capacity. Nexgen Animal Health is a US-based company specializes in the formulation of innovative products and drugs compounds for animals.

Regional Outlook

North America was the largest region in the animal drug compounding market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Animal Drug Compounding Market?

The animal drug compounding market consists of sales of flavored medications, suppositories, and ophthalmic preparations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.